Do analysts rate CRVO or RFAI?

CervoMed presently has a consensus target price of $21.00, indicating a potential upside of 764.20%. Given CervoMed's stronger consensus rating and higher probable upside, analysts clearly believe CervoMed is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, CRVO or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than CervoMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CervoMed $4.01M 9.16 -$26.97M -$3.22 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Which has stronger valuation & earnings, CRVO or VTVT?

vTv Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CervoMed $4.01M 9.16 -$26.97M -$3.22 N/A vTv Therapeutics $1.02M 122.84 -$26.97M -$1.06 N/A

Is CRVO or VTVT more profitable?

vTv Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. vTv Therapeutics' return on equity of -6.27% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets CervoMed -672.80% -156.02% -128.34% vTv Therapeutics N/A -6.27% -5.06%

CervoMed (CRVO) Competitors

$2.43 -0.12 (-4.71%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.48 +0.05 (+2.14%)

As of 09/18/2026 07:51 PM Eastern

Compare

CRVO vs. NRXP, RFAI, MIST, UNCY, and VTVT

Should you buy CervoMed stock or one of its competitors? CervoMed's main competitors and comparable companies include NRx Pharmaceuticals (NRXP), RF Acquisition Corp II (RFAI), Milestone Pharmaceuticals (MIST), Unicycive Therapeutics (UNCY), and vTv Therapeutics (VTVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CervoMed compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

NRx Pharmaceuticals has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.64, suggesting that its share price is 164% less volatile than the broader market.

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 35.8% of CervoMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CervoMed has a net margin of -672.80% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
CervoMed	-672.80%	-156.02%	-128.34%

NRx Pharmaceuticals presently has a consensus target price of $34.50, indicating a potential upside of 939.16%. CervoMed has a consensus target price of $21.00, indicating a potential upside of 764.20%. Given NRx Pharmaceuticals' higher possible upside, equities analysts clearly believe NRx Pharmaceuticals is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, NRx Pharmaceuticals had 10 more articles in the media than CervoMed. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 0 mentions for CervoMed. NRx Pharmaceuticals' average media sentiment score of 0.70 beat CervoMed's score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
NRx Pharmaceuticals	Positive
CervoMed	Neutral

CervoMed has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	116.87	-$28.62M	-$0.55	N/A
CervoMed	$4.01M	9.16	-$26.97M	-$3.22	N/A

Summary

NRx Pharmaceuticals beats CervoMed on 9 of the 17 factors compared between the two stocks.

How does CervoMed compare to RF Acquisition Corp II?

CervoMed (NASDAQ:CRVO) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

25.2% of CervoMed shares are held by institutional investors. 35.8% of CervoMed shares are held by insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CervoMed presently has a consensus target price of $21.00, indicating a potential upside of 764.20%. Given CervoMed's stronger consensus rating and higher probable upside, analysts clearly believe CervoMed is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

RF Acquisition Corp II has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. RF Acquisition Corp II's return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-156.02%	-128.34%
RF Acquisition Corp II	N/A	N/A	N/A

In the previous week, RF Acquisition Corp II had 11 more articles in the media than CervoMed. MarketBeat recorded 11 mentions for RF Acquisition Corp II and 0 mentions for CervoMed. CervoMed's average media sentiment score of 0.00 equaled RF Acquisition Corp II'saverage media sentiment score.

Company	Overall Sentiment
CervoMed	Neutral
RF Acquisition Corp II	Neutral

CervoMed has a beta of -0.64, indicating that its share price is 164% less volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

RF Acquisition Corp II has lower revenue, but higher earnings than CervoMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.16	-$26.97M	-$3.22	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

Summary

CervoMed and RF Acquisition Corp II tied by winning 6 of the 12 factors compared between the two stocks.

How does CervoMed compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 35.8% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Milestone Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.64, indicating that its stock price is 164% less volatile than the broader market.

Milestone Pharmaceuticals presently has a consensus price target of $6.40, suggesting a potential upside of 598.84%. CervoMed has a consensus price target of $21.00, suggesting a potential upside of 764.20%. Given CervoMed's higher probable upside, analysts plainly believe CervoMed is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Milestone Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -156.02% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
CervoMed	-672.80%	-156.02%	-128.34%

In the previous week, Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled CervoMed'saverage media sentiment score.

Company	Overall Sentiment
Milestone Pharmaceuticals	Neutral
CervoMed	Neutral

CervoMed has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	73.56	-$63.06M	-$0.69	N/A
CervoMed	$4.01M	9.16	-$26.97M	-$3.22	N/A

Summary

Milestone Pharmaceuticals and CervoMed tied by winning 6 of the 12 factors compared between the two stocks.

How does CervoMed compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Unicycive Therapeutics presently has a consensus target price of $18.75, suggesting a potential upside of 290.63%. CervoMed has a consensus target price of $21.00, suggesting a potential upside of 764.20%. Given CervoMed's stronger consensus rating and higher possible upside, analysts clearly believe CervoMed is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Unicycive Therapeutics had 17 more articles in the media than CervoMed. MarketBeat recorded 17 mentions for Unicycive Therapeutics and 0 mentions for CervoMed. CervoMed's average media sentiment score of 0.00 beat Unicycive Therapeutics' score of -0.01 indicating that CervoMed is being referred to more favorably in the news media.

Company	Overall Sentiment
Unicycive Therapeutics	Neutral
CervoMed	Neutral

Unicycive Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Unicycive Therapeutics' return on equity of -91.50% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
CervoMed	-672.80%	-156.02%	-128.34%

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 35.8% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Unicycive Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.64, suggesting that its stock price is 164% less volatile than the broader market.

Unicycive Therapeutics has higher earnings, but lower revenue than CervoMed. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	196.59	-$26.56M	-$1.75	N/A
CervoMed	$4.01M	9.16	-$26.97M	-$3.22	N/A

Summary

Unicycive Therapeutics beats CervoMed on 10 of the 17 factors compared between the two stocks.

How does CervoMed compare to vTv Therapeutics?

CervoMed (NASDAQ:CRVO) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, vTv Therapeutics had 2 more articles in the media than CervoMed. MarketBeat recorded 2 mentions for vTv Therapeutics and 0 mentions for CervoMed. vTv Therapeutics' average media sentiment score of 0.37 beat CervoMed's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CervoMed	Neutral
vTv Therapeutics	Neutral

vTv Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. vTv Therapeutics' return on equity of -6.27% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-156.02%	-128.34%
vTv Therapeutics	N/A	-6.27%	-5.06%

vTv Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.16	-$26.97M	-$3.22	N/A
vTv Therapeutics	$1.02M	122.84	-$26.97M	-$1.06	N/A

CervoMed currently has a consensus target price of $21.00, suggesting a potential upside of 764.20%. vTv Therapeutics has a consensus target price of $55.83, suggesting a potential upside of 75.58%. Given CervoMed's higher probable upside, equities research analysts clearly believe CervoMed is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

25.2% of CervoMed shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 35.8% of CervoMed shares are held by insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CervoMed has a beta of -0.64, indicating that its stock price is 164% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

Summary

vTv Therapeutics beats CervoMed on 10 of the 15 factors compared between the two stocks.

Get CervoMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVO vs. The Competition

Export

Metric	CervoMed	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$36.74M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-0.75	797.25	275.49	25.40
Price / Sales	9.16	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	1.23	10.53	10.46	6.33
Net Income	-$26.97M	$2.82B	$3.49B	$358.33M
7 Day Performance	-5.45%	1.69%	0.59%	1.12%
1 Month Performance	-5.08%	0.24%	-1.74%	-2.39%
1 Year Performance	-68.81%	3.95%	18.13%	5.35%

CervoMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVO CervoMed	1.945 of 5 stars	$2.43 -4.7%	$21.00 +764.2%	-68.8%	$36.74M	$4.01M	N/A	15
NRXP NRx Pharmaceuticals	1.9634 of 5 stars	$3.46 -1.0%	$34.50 +898.6%	+11.8%	$149.60M	$1.23M	N/A	2
RFAI RF Acquisition Corp II	1.0355 of 5 stars	$42.31 +1.9%	N/A	+274.9%	$148.63M	N/A	N/A	N/A	Gap Down
MIST Milestone Pharmaceuticals	1.8054 of 5 stars	$1.14 -5.4%	$6.40 +463.9%	-52.3%	$141.31M	$1.55M	N/A	30
UNCY Unicycive Therapeutics	3.0792 of 5 stars	$5.04 -2.4%	$18.75 +272.2%	+21.2%	$140.28M	$680K	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVO) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CervoMed (CRVO) Competitors

CRVO vs. NRXP, RFAI, MIST, UNCY, and VTVT

How does CervoMed compare to NRx Pharmaceuticals?

Summary

How does CervoMed compare to RF Acquisition Corp II?

Summary

How does CervoMed compare to Milestone Pharmaceuticals?

Summary

How does CervoMed compare to Unicycive Therapeutics?

Summary

How does CervoMed compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CervoMed (CRVO) Competitors

CRVO vs. NRXP, RFAI, MIST, UNCY, and VTVT

How does CervoMed compare to NRx Pharmaceuticals?

Which has more risk and volatility, NRXP or CRVO?

Do institutionals and insiders hold more shares of NRXP or CRVO?

Is NRXP or CRVO more profitable?

Do analysts rate NRXP or CRVO?

Does the media favor NRXP or CRVO?

Which has better earnings & valuation, NRXP or CRVO?

Summary

How does CervoMed compare to RF Acquisition Corp II?

Do insiders & institutionals believe in CRVO or RFAI?

Do analysts rate CRVO or RFAI?

Is CRVO or RFAI more profitable?

Does the media refer more to CRVO or RFAI?

Which has more volatility & risk, CRVO or RFAI?

Which has better valuation and earnings, CRVO or RFAI?

Summary

How does CervoMed compare to Milestone Pharmaceuticals?

Do insiders and institutionals hold more shares of MIST or CRVO?

Which has more volatility and risk, MIST or CRVO?

Do analysts recommend MIST or CRVO?

Is MIST or CRVO more profitable?

Does the media prefer MIST or CRVO?

Which has higher valuation and earnings, MIST or CRVO?

Summary

How does CervoMed compare to Unicycive Therapeutics?

Do analysts rate UNCY or CRVO?

Does the media prefer UNCY or CRVO?

Is UNCY or CRVO more profitable?

Do insiders and institutionals hold more shares of UNCY or CRVO?

Which has more risk & volatility, UNCY or CRVO?

Which has stronger valuation and earnings, UNCY or CRVO?

Summary

How does CervoMed compare to vTv Therapeutics?

Does the media refer more to CRVO or VTVT?

Is CRVO or VTVT more profitable?

Which has stronger valuation & earnings, CRVO or VTVT?

Do analysts rate CRVO or VTVT?

Do institutionals and insiders have more ownership in CRVO or VTVT?

Which has more volatility and risk, CRVO or VTVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools